profit from every $100 of sales.
$0$100
ARS Pharmaceuticals
$3.15+12.90% today
-64.4% in 1 year
1-year low $2.651-year high $13.06
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ARS Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $1.32 million in 2022 to $84.3 million in 2025, with -$171 million of profit last year.
SalesProfit
ARS Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ARS Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads ARS Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 89 | 84 | |
| – | 0 | 88 | 64 | |
| -36 | -68 | -3 | -179 | |
| -35 | -68 | 8 | -169 | |
| -35 | -54 | 8 | -171 | |
| -0.87 | -0.57 | 0.08 | -1.74 | |
| – | 100.0% | 98.9% | 75.8% | |
| -2,698.8% | -225,066.7% | -3.5% | -212.9% | |
| -2,635.4% | -181,216.7% | 9.0% | -203.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 281 | 233 | 351 | 328 |
| Cash | 211 | 71 | 51 | 41 |
| Total debt | 0 | 0 | 0 | 96 |
| Total liabilities | 9 | 2 | 94 | 213 |
| 273 | 231 | 257 | 114 | |
| 40 | 95 | 102 | 99 | |
| -10.3% | -23.1% | 2.5% | -63.3% | |
| -12.7% | -23.6% | 3.1% | -149.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -40 | -59 | 14 | -171 | |
| 0 | 0 | 1 | 0 | |
| -40 | -59 | 13 | -171 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 9 | 15 | 22 |
Valuation
- –
- –
- –
- 7.4×
- 3.8×
- –
- –
- -54.1%
- -54.1%
- 0.0%
Profitability
- 75.8%
- -212.9%
- -203.3%
- -203.3%
- -62.0%
- -4.6%
- -100.3%
- -52.3%
- -62.2%
- 15.6%
Growth
- +300.1%
- –
- −1,418.5%
- –
- +35.9%
Financial health
- –
- 0.85
- 29.6%
- –
- 7.28
- 7.06
- 0.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 948
Bottom 1%of 985
What analysts expect
- Average price target
- $25.50
- Range
- $25.00 – $26.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.61 | -0.53 | −15.1% |
| Mar 9, 2026 | -0.42 | -0.42 | +0.0% |
| Nov 10, 2025 | -0.52 | -0.45 | −15.6% |
| Aug 13, 2025 | -0.46 | -0.41 | −12.2% |
| May 14, 2025 | -0.35 | -0.35 | +0.0% |
| Mar 20, 2025 | 0.52 | -0.04 | +1,400.0% |
| Nov 13, 2024 | -0.20 | -0.18 | −11.1% |
| Aug 6, 2024 | -0.13 | -0.12 | −8.3% |
News
Ionis Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 6, 2026ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha · Nov 5, 2026Vertex Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 1, 2026Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineYahoo Finance · Oct 27, 2026Jazz Pharmaceuticals sees $755M IPR&D charge in Q3 resultsSeeking Alpha · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
34No pass
Philip Fisher
44No pass
Peter Lynch
36No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
40No pass
Questions about ARS Pharmaceuticals
Is ARS Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ARS Pharmaceuticals AI analysis
What does ARS Pharmaceuticals do?
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. It is in Biotechnology.
Does ARS Pharmaceuticals pay a dividend?
No. ARS Pharmaceuticals does not pay a dividend at the moment.
Is ARS Pharmaceuticals stock halal?
Questionable. ARS Pharmaceuticals sits in a grey zone: its debt is 30% of its market value, between 30% and 33%. How we check
How has ARS Pharmaceuticals stock done over the past year?
Down 64.4% over the past twelve months, to $3.15. It traded between $2.65 and $13.06 and is 75.9% below its high.
Who are ARS Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with ARS Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.